PRPH ProPhase Labs, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 868278 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY138.9%
TTM net income YoY45.8%
TTM EPS YoY91.5%
Revenue 3-yr CAGR-63.4%
Net income 3-yr CAGR—
Margins
Gross margin16.8%
Operating margin-404.5%
Net margin-583.9%
FCF margin—
EBITDA margin-320.1%
Returns
ROE-539.7%
ROA-45.2%
ROIC (approx.)-302.2%
Asset turnover0.08x
Leverage & solvency
Liabilities / assets105.4%
Debt / equity—
Current ratio0.05x
Interest coverage-2.15x
Cash quality & payout
Operating cash flow / net income0.25x
Accruals ratio-34.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.01M | $1.17M | $784,000 | $883,000 | $1.25M | $1.43M | -$2.48M | $1.42M |
| Cost of revenue | $785,000 | $874,000 | $537,000 | $1.01M | $513,000 | $905,000 | -$3.41M | $1.20M |
| Gross profit | $226,000 | $295,000 | $247,000 | -$123,000 | $734,000 | $526,000 | $924,000 | $215,000 |
| R&D expense | — | — | $0 | $6,000 | $4,000 | $97,000 | $61,000 | $122,000 |
| SG&A expense | $2.87M | $2.72M | $5.97M | $4.63M | $4.62M | $4.09M | $15.43M | $6.57M |
| Operating income | -$2.65M | -$2.43M | -$5.73M | -$4.76M | -$3.89M | -$3.66M | -$14.57M | -$6.48M |
| Interest expense | $791,000 | $651,000 | $4.26M | $1.55M | $587,000 | $539,000 | $1.03M | $993,000 |
| Pretax income | -$3.04M | -$3.80M | -$8.02M | -$7.00M | -$3.69M | -$4.68M | -$15.96M | -$7.47M |
| Income tax | $12,000 | $1.37M | -$622,000 | -$157,000 | $779,000 | $0 | $14.56M | -$2.51M |
| Net income | -$3.05M | -$5.17M | -$7.40M | -$6.84M | -$4.47M | $3.97M | -$34.36M | -$6.59M |
| EBITDA | -$2.02M | -$1.46M | -$4.76M | -$4.07M | -$2.88M | -$2.18M | -$13.04M | -$4.95M |
| EPS (basic) | -0.22 | -0.42 | — | -0.16 | -1.08 | 1.13 | — | -0.35 |
| EPS (diluted) | -0.22 | -0.42 | — | -0.16 | -1.08 | 1.13 | — | -0.35 |
| Weighted avg. shares (diluted) | 14.02M | 12.32M | — | 41.54M | 4.15M | 3.52M | — | 19.08M |
| Banking | ||||||||
| Provision for credit losses | — | — | — | — | — | — | $0 | $0 |
| Balance sheet | ||||||||
| Cash & equivalents | $20,000 | $31,000 | $90,000 | $405,000 | $169,000 | $88,000 | $678,000 | $501,000 |
| Short-term investments | — | — | $0 | — | $2,000 | — | $3.13M | $2,000 |
| Receivables | $1.54M | $1.54M | $1.54M | $3.28M | $20.09M | $20.20M | $20.06M | $31.64M |
| Inventory | $70,000 | $70,000 | $70,000 | $266,000 | $830,000 | $1.15M | $1.14M | $3.97M |
| Current assets | $2.80M | $2.85M | $3.15M | $7.77M | $24.57M | $24.77M | $30.64M | $42.23M |
| PP&E, net | $1.39M | $1.71M | $2.03M | $2.35M | $3.58M | $6.57M | $7.50M | $13.85M |
| Goodwill | $3.97M | $3.97M | $3.97M | $3.97M | $5.23M | $5.23M | $5.23M | $5.23M |
| Intangibles | $5.88M | $6.52M | $7.17M | $7.81M | $8.46M | $9.10M | $9.75M | $10.40M |
| Total assets | $57.41M | $58.47M | $59.87M | $65.70M | $42.04M | $50.11M | $63.20M | $91.81M |
| Current liabilities | $58.09M | $55.67M | $53.08M | $55.29M | $25.63M | $24.05M | $32.13M | $28.70M |
| Short-term debt | — | — | — | — | — | $2.45M | $3.21M | $2.67M |
| Total liabilities | $60.52M | $58.90M | $56.36M | $58.84M | $30.61M | $34.99M | $55.85M | $53.68M |
| Shareholders' equity | -$3.11M | -$435,000 | $3.51M | $6.86M | $11.44M | $15.12M | $7.35M | $38.13M |
| Shares outstanding | 14.02M | 14.02M | 8.97M | 41.54M | 41.54M | 41.54M | 2.99M | 19.08M |
| Cash flow statement | ||||||||
| Operating cash flow | -$78,000 | -$748,000 | -$1.23M | -$3.49M | -$247,000 | -$3.38M | -$3.52M | -$4.04M |
| Capital expenditure | — | — | $0 | $0 | $0 | $0 | -$235,000 | -$1,000 |
| Free cash flow | — | — | -$1.23M | -$3.49M | -$247,000 | -$3.38M | -$3.28M | -$4.04M |
| Investing cash flow | $0 | $12,000 | $0 | $0 | $67,000 | $853,000 | -$40,000 | -$97,000 |
| Financing cash flow | $67,000 | $677,000 | $915,000 | $3.72M | $261,000 | $1.94M | $3.73M | $2.86M |
| Depreciation & amortization | $623,000 | $962,000 | $963,000 | $698,000 | $1.01M | $1.48M | $1.52M | $1.53M |
| Stock-based compensation | $375,000 | $390,000 | $433,000 | $400,000 | $500,000 | $521,000 | $617,000 | $600,000 |
| Share buybacks | — | — | — | — | — | — | $0 | $0 |
Free plan shows the latest 8 periods; Pro shows all 67 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.